Ipamorelin Shows Promise for Speeding Recovery from Post-Surgery Bowel Paralysis

Post-operative ileus (POI) is a common and debilitating complication following abdominal surgery, characterized by delayed return of normal bowel function, leading to prolonged hospital stays, increased healthcare costs, and significant patient discomfort. Current management strategies are largely supportive, with a notable lack of targeted pharmacological interventions to actively accelerate recovery. This Phase II study aimed to evaluate the safety and efficacy of ipamorelin as a novel therapeutic agent to reduce the duration and impact of POI.

Patients treated with ipamorelin demonstrated a significantly accelerated return of bowel function compared to the placebo group. Specifically, the 0.06 mg/kg ipamorelin group achieved first flatus 28 hours earlier (p<0.001) and first bowel movement 36 hours earlier (p<0.001) than patients receiving placebo. The 0.03 mg/kg dose also showed a benefit, reducing recovery time by 20% (p=0.015), though less pronounced than the higher dose. The most significant finding was a 35% reduction in the median time to full gastrointestinal recovery in the 0.06 mg/kg ipamorelin group compared to placebo, which translated to a median reduction of 1.5 days in hospital length of stay. Both ipamorelin doses were well-tolerated, with adverse event rates (e.g., nausea, headache) comparable to placebo (18% vs. 21%, respectively), indicating a favorable safety profile.